menu search

MRUS / Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns
Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the stock is mixed and price structure has broken down. Updates from its major clinical programs are the key drivers to equity returns for MRUS at this stage in its lifecycle. Read More
Posted: Aug 30 2023, 21:22
Author Name: Seeking Alpha
Views: 112513

MRUS News  

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

By Zacks Investment Research
October 17, 2023

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t more_horizontal

Merus Announces Business Update Conference Call

By GlobeNewsWire
October 15, 2023

Merus Announces Business Update Conference Call

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinica more_horizontal

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

By Seeking Alpha
August 30, 2023

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes pro more_horizontal

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $ more_horizontal

Merus stock jumps 10% after FDA's action on cancer drug

By Market Watch
June 29, 2023

Merus stock jumps 10% after FDA's action on cancer drug

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administr more_horizontal

Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy

By Zacks Investment Research
May 11, 2023

Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy

Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors? more_horizontal

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 4, 2023

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $ more_horizontal

Merus: Dutch Drug Developer With An Interesting Platform

By Seeking Alpha
April 4, 2023

Merus: Dutch Drug Developer With An Interesting Platform

Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma. more_horizontal


Search within

Pages Search Results: